Stay in the Know

Want to know more about ALUNBRIG® (brigatinib)? Sign up now to receive useful information and updates.

Want to know more about treatment with ALUNBRIG? Request our Patient Information Kit, which includes helpful resources for patients and loved ones.

*Required Fields

Maximum 15-character limit
Maximum 15-character limit
Maximum 20-character limit
Please select menu item

Request a Patient Information Kit!

New to ALUNBRIG? The patient information kit is a comprehensive resource for you and your loved ones that includes important information about starting therapy for ALK+ metastatic NSCLC with ALUNBRIG, including:

  • Patient Brochure
  • Care Partner Brochure
  • Patient Dosing Guide
  • Medication and Symptom Trackers
  • Financial Assistance Information

Maximum 30-character limit
Maximum 30-character limit
Maximum 15-character limit
Please select menu item
Please enter a valid zip code for the United States

By clicking Submit, you agree to receive product and disease-state information from Takeda, its affiliates, service providers, and co-promotion partners.

 

Submit Please fill in required fields


ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More